Health Care Professionals

OUR MEDICINES

Santhera is passionate about medical science and about developing new medical treatments for patients with mitochondrial diseases. Our focus is on the development of treatments for neuromuscular and neuro-ophthalmological diseases that currently lack treatment options.

Raxone in LHON

In September 2015, we received European Marketing Authorization for Raxone in the treatment of patients with Leber's hereditary optic neuropathy (LHON). This makes Raxone (idebenone 150 mg) the first and only medicine approved for this condition. Indeed, it is the first medicine approved for any mitochondrial disorder: a major milestone in addressing the unmet medical need represented by this group of rare diseases.

▼The European Medicines Agency (EMA) has indicated that this medicine is subject to additional monitoring.

Our pipeline

Raxone is also being investigated for the treatment of Duchenne muscular dystrophy (DMD) and primary progressive multiple sclerosis (PPMS). In addition, Santhera’s pipeline includes omigapil, an investigational drug with anti-apoptotic properties, a compound in development to address unmet medical needs for patients with congenital muscular dystrophy (CMD).

Pipeline of developed medical drugs in medical science

If you are a healthcare professional, please click below to find out more about our development pipeline:

Our pipeline: Raxone in DMD

Raxone in Duchenne muscular dystrophy (DMD) If you are a healthcare professional please click below to find out more about Raxone in Duchenne muscular dystrophy (DMD): Learn More

Our pipeline: Raxone in PPMS

Raxone in primary progressive multiple sclerosis (PPMS) If you are a healthcare professional please click below to find out more about Raxone in primary progressive multiple sclerosis (PPMS): Learn More

Our pipeline: Omigapil

Raxone in congenital muscular dystrophy (CMD) If you are a healthcare professional please click below to find out more about omigapil in congenital muscular dystrophy (CMD): Learn More

Access to Raxone

Access for Health Care Professionals to Raxone

Access to Raxone varies by the country from which the order is being placed. Bottles containing 180 tablets of Raxone (idebenone 150 mg) are currently available as follows:

European Union Member States, Norway and Iceland
For availability in one of the countries above please contact order@santhera.com.

Switzerland
For availability in Switzerland please contact Spezialapotheke MediService:
Email: pharmacare@mediservice.ch
Phone: +41 800 220 222 
Fax: +41 32 686 28 05

Albania, Bosnia and Herzegovina, Kosovo, Montenegro, Republic of Macedonia (F.Y.R.O.M.), Serbia
For availability in these countries please contact Clinigen Group:
E-Mail: global@clinigengroup.com
Phone: +44 1932 824 123

United States of America
Raxone/idebenone is NOT approved for use in the U.S. and is NOT available for purchase. Note that Santhera is running a study with idebenone in boys with Duchenne muscular dystrophy (DMD) currently taking steroids that you/your child may be eligible for. For additional information regarding this ongoing trial, please email john.karafilidis@santhera.com.
For medical inquiries regarding idebenone, please call: +1 800 887 6915

All other countries not included above
For availability in all other countries not included above please contact Masters Speciality Pharma: 
Email: orders@masters-sp.com
Phone: +44 208 327 0900 
Fax: +44 208 327 0901 
Online: www.masters-sp.com